Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor

Marcos A. Soares de Oliveira; Silvia Hilt; Che Wei Chang; Changwon Lee; John C Voss; James W. Chan

doi:10.1364/AO.399307

Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor

Marcos A. Soares de Oliveira, Silvia Hilt, Che Wei Chang, Changwon Lee, John C Voss, James W. Chan

Research output: Contribution to journal › Article › peer-review

Abstract

Soluble, small amyloid-β oligomers (AβO) are recognized as significant contributors to the pathology of Alzheimer’s disease (AD). Although drugs for treating AD symptoms have been approved, no therapy targeting amyloid-β (Aβ) capable of modifying the course of the disease is available. In an effort to develop a label-free method for screening new anti-AD therapeutic agents, we show the use of a surface-enhanced Raman scattering (SERS) active substrate for detecting the interactions between Aβ peptides and spin-labeled fluorine (SLF), a peptide aggregation inhibitor. Changes in the peak positions and intensity ratios of two spectral peaks near 1600 cm⁻1 and 2900 cm⁻¹ can be used to monitor the molecular interactions between SLF and Aβ. This study demonstrates the potential of SERS spectroscopy for rapidly screening and identifying new anti-Aβ therapeutic agents.

Original language	English (US)
Pages (from-to)	7490-7495
Number of pages	6
Journal	Applied Optics
Volume	59
Issue number	25
DOIs	https://doi.org/10.1364/AO.399307
State	Published - Sep 1 2020

ASJC Scopus subject areas

Atomic and Molecular Physics, and Optics
Engineering (miscellaneous)
Electrical and Electronic Engineering

Access to Document

10.1364/AO.399307

Cite this

@article{40e4308183274099a93136b3a07decb7,

title = "Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor",

abstract = "Soluble, small amyloid-β oligomers (AβO) are recognized as significant contributors to the pathology of Alzheimer{\textquoteright}s disease (AD). Although drugs for treating AD symptoms have been approved, no therapy targeting amyloid-β (Aβ) capable of modifying the course of the disease is available. In an effort to develop a label-free method for screening new anti-AD therapeutic agents, we show the use of a surface-enhanced Raman scattering (SERS) active substrate for detecting the interactions between Aβ peptides and spin-labeled fluorine (SLF), a peptide aggregation inhibitor. Changes in the peak positions and intensity ratios of two spectral peaks near 1600 cm−1 and 2900 cm−1 can be used to monitor the molecular interactions between SLF and Aβ. This study demonstrates the potential of SERS spectroscopy for rapidly screening and identifying new anti-Aβ therapeutic agents.",

author = "{Soares de Oliveira}, {Marcos A.} and Silvia Hilt and Chang, {Che Wei} and Changwon Lee and Voss, {John C} and Chan, {James W.}",

year = "2020",

month = sep,

day = "1",

doi = "10.1364/AO.399307",

language = "English (US)",

volume = "59",

pages = "7490--7495",

journal = "Applied Optics",

issn = "0003-6935",

publisher = "The Optical Society",

number = "25",

}

TY - JOUR

T1 - Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor

AU - Soares de Oliveira, Marcos A.

AU - Hilt, Silvia

AU - Chang, Che Wei

AU - Lee, Changwon

AU - Voss, John C

AU - Chan, James W.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Soluble, small amyloid-β oligomers (AβO) are recognized as significant contributors to the pathology of Alzheimer’s disease (AD). Although drugs for treating AD symptoms have been approved, no therapy targeting amyloid-β (Aβ) capable of modifying the course of the disease is available. In an effort to develop a label-free method for screening new anti-AD therapeutic agents, we show the use of a surface-enhanced Raman scattering (SERS) active substrate for detecting the interactions between Aβ peptides and spin-labeled fluorine (SLF), a peptide aggregation inhibitor. Changes in the peak positions and intensity ratios of two spectral peaks near 1600 cm−1 and 2900 cm−1 can be used to monitor the molecular interactions between SLF and Aβ. This study demonstrates the potential of SERS spectroscopy for rapidly screening and identifying new anti-Aβ therapeutic agents.

AB - Soluble, small amyloid-β oligomers (AβO) are recognized as significant contributors to the pathology of Alzheimer’s disease (AD). Although drugs for treating AD symptoms have been approved, no therapy targeting amyloid-β (Aβ) capable of modifying the course of the disease is available. In an effort to develop a label-free method for screening new anti-AD therapeutic agents, we show the use of a surface-enhanced Raman scattering (SERS) active substrate for detecting the interactions between Aβ peptides and spin-labeled fluorine (SLF), a peptide aggregation inhibitor. Changes in the peak positions and intensity ratios of two spectral peaks near 1600 cm−1 and 2900 cm−1 can be used to monitor the molecular interactions between SLF and Aβ. This study demonstrates the potential of SERS spectroscopy for rapidly screening and identifying new anti-Aβ therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=85090388384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090388384&partnerID=8YFLogxK

U2 - 10.1364/AO.399307

DO - 10.1364/AO.399307

M3 - Article

C2 - 32902446

AN - SCOPUS:85090388384

VL - 59

SP - 7490

EP - 7495

JO - Applied Optics

JF - Applied Optics

SN - 0003-6935

IS - 25

ER -

Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation inhibitor

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this